Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT01983501 |
Title | A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Oncothyreon Inc. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | CAN |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
University of Alabama | Birmingham | Alabama | 35294 | United States | Details | |
University of Colorado Cancer Center | Aurora | Colorado | 80045 | United States | Details | |
University of Kansas | Kansas City | Kansas | 66160 | United States | Details | |
Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
Providence Cancer Center | Portland | Oregon | 97213 | United States | Details | |
Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | United States | Details | |
Northwest Medical Specialties | Tacoma | Washington | 98045 | United States | Details | |
London Health Sciences Centre | London | Ontario | N6A 5W9 | Canada | Details | |
Princess Margaret Cancer Centre | Toronto | Ontario | M5T 2M9 | Canada | Details | |
Hospital de la Cite-de-la-Sante | Laval | Quebec | H7M 3L9 | Canada | Details | |
Jewish General Hospital | Montreal | Quebec | H3T 1E2 | Canada | Details |